Abstract

In vitro culture models were used to characterize the effects of chemotherapeutic drugs and of LH on somatic cells from prepuberal mouse ovaries. All cell types (pre- and granulosa cells, pre-thecal and OSE cells) underwent apoptosis following Epirubicin (0.5μM) exposure for 24hrs (about 60%) and 48hrs (>80%). Cisplatin (10μM) and the Cyclophosphamide active metabolite, Phosphoramide Mustard (10μM), didn’t cause apoptosis in 90% of pre-thecal and pre-granulosa cells up to 72hrs of exposure, although they suffered extensive DNA damage and cell cycle arrest, and acquired stress induced premature senescence (SIPS) features. Cultured granulosa cells didn’t show evident DNA damage and remained viable without acquiring SIPS features; OSE cells were resistant to apoptosis and SIPS but not to DNA damage. These latter, like pre-thecal and pre-granulosa cells, were able of efficient DNA repair involving MLH1-dependent MMR pathways. SIPS features were also observed in ovary after in vivo treatment with Cisplatin. LH (200mIU/mL) didn’t significantly influence apoptosis, SIPS and DNA damage but favoured DNA repair. These results show that somatic cells of prepuberal ovary response to drugs in different ways, either undergoing apoptosis or SIPS, either showing resistance to Cisplatin and Phosphoramide Mustard. Moreover, a new role of LH in promoting DNA repair was shown.

Highlights

  • Ovarian reserve exhaustion causes menopause, a phenomenon that occurs in women of an average age of 50 years

  • Cells were analyzed by RT-polymerase chain reaction (PCR), Western Blotting (WB), IHC and IF, at different culture times for the expression of markers of epithelial, granulosa (GCs) and follicular theca (TCs) cells

  • We reported that 200 mIU/mL Luteinizing Hormone (LH), through its action on the somatic cells of prepuberal ovaries, protected primordial follicles (PMFs)-enclosed oocytes (POs) from CS-induced apoptosis [17]

Read more

Summary

Introduction

Ovarian reserve exhaustion causes menopause, a phenomenon that occurs in women of an average age of 50 years. Wallace and Kelsey [7], mathematically estimated that in the majority of 30 year old women is present only 12% of their maximum pre-birth number of PMFs and that this percentage decline to 3% at the age of 40. This process continues until fewer than a thousand follicles remain in the ovary defining the beginning of the menopause [7, 8]. It is well recognized that, under certain www.aging-us.com circumstances, this process can be deregulated leading to an acceleration of the ovarian reserve exhaustion, a phenomenon collectively known as Premature Ovarian Insufficiency (POI) [9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call